Home › Job titles › Regulatory Affairs Manager
Regulatory Affairs Manager: H-1B salaries
73 labor condition applications used the job title Regulatory Affairs Manager. Median offered base salary $125,000; middle half $110,718–$142,184.
Applications (LCAs)73
Median offered salary$125,000
Middle half of salaries$110,718–$142,184
10th–90th percentile$94,702–$166,519
Immigration lawyer, recruiter or employer? Feature your service at the top of this page — $99 for 30 days →
Employers
| Employer | LCAs | Median salary |
|---|
| Freyr,Inc. | 4 | $124,180 |
| Rising Pharma Holdings Inc. | 4 | $106,838 |
| Edenbridge Pharmaceuticals, LLC | 3 | $125,000 |
| Roche Sequencing Solutions, Inc. | 3 | $140,504 |
| Withings, Inc. | 3 | $117,000 |
| Galt Pharmaceuticals, LLC | 3 | $95,472 |
| Rentschler Biopharma, Inc. | 2 | $140,000 |
| Teva Pharmaceuticals USA, Inc. | 2 | $116,866 |
| Becton, Dickinson and Company | 2 | $170,000 |
| Siemens Medical Solutions USA, Inc. | 2 | $139,059 |
| St. Jude Medical, Cardiology Division, Inc. | 2 | $117,855 |
| Inari Medical, Inc. | 2 | $173,043 |
| Zimmer, Inc. | 2 | $135,466 |
| Kerry Inc. | 2 | $132,862 |
| Long Shine LLC | 2 | $84,000 |
| PAI Holdings LLC | 2 | $106,392 |
| Instrumentation Laboratory Company | 1 | $150,176 |
| ForDoz Pharma Corp | 1 | $114,999 |
| August Bioservices, LLC | 1 | $74,318 |
| Evergreen Theragnostics, Inc. | 1 | $115,000 |
| Azurity Pharmaceuticals, Inc. | 1 | $145,000 |
| Medtronic, Inc. | 1 | $99,736 |
| Think Logic Systems Inc | 1 | $120,640 |
| Hetero USA Inc. | 1 | $185,000 |
| AMP Solutions LLC | 1 | $109,824 |
| Planet Innovation, Inc. | 1 | $140,000 |
| Cornerstone Medical (USA) Inc. | 1 | $155,000 |
| Applied Medical Resources Corporation | 1 | $128,000 |
| Ascensia Diabetes Care US Inc. | 1 | $144,891 |
| Bio-Rad Laboratories, Inc. | 1 | $155,000 |
| RK Pharma Inc | 1 | $140,483 |
| AstraZeneca Pharmaceuticals LP | 1 | $127,694 |
| New York City Criminal Justice Agency, Inc. | 1 | $102,315 |
| NeoImmuneTech, Inc. | 1 | $131,250 |
| BioPathogenix LLC. | 1 | $100,000 |
| Arteriocyte Medical Systems, Inc. | 1 | $128,205 |
| Prestonwood Home Healthcare LLC | 1 | $87,776 |
| Carefirst Rehab, LLC | 1 | $62,941 |
| scPharmaceuticals Inc. | 1 | $120,640 |
| ND Global Consulting Services Inc. | 1 | $166,400 |
| Nevakar Injectables Inc. | 1 | $310,000 |
| Granules Pharmaceuticals Inc. | 1 | $82,000 |
| New Erie Scientific LLC | 1 | $114,750 |
| Ambio, Inc. | 1 | $75,000 |
| Bachem Americas, Inc. | 1 | $104,000 |
| Apyx Medical Corporation | 1 | $154,294 |
| Ortho-Clinical Diagnostics, Inc. | 1 | $100,464 |
| Endovascular Engineering | 1 | $168,064 |
| Guardant Health, Inc. | 1 | $135,678 |
By wage level
| Wage level | Median salary |
|---|
| Level I (entry) | $108,675 |
| Level II (qualified) | $129,625 |
| Level III (experienced) | $155,000 |
| Level IV (fully competent) | $126,704 |
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
By fiscal year
| Fiscal year | LCAs | Median salary |
|---|
| FY2023 | 25 | $125,000 |
| FY2024 | 21 | $123,110 |
| FY2025 | 19 | $120,000 |
| FY2026 | 5 | $127,555 |
Cities
- Parsippany, NJ4
- East Brunswick, NJ4
- Irvine, CA3
- San Jose, CA3
- Boston, MA3
- Milford, MA2
- Franklin Lakes, NJ2
- Malvern, PA2
- San Diego, CA2
- Atlanta, GA2
- Beloit, WI2
- Ontario, CA2
- Plainsboro, NJ2
- Bridgewater, NJ2
- Bedford, MA1
- East Windsor, NJ1
- Nashville, TN1
- Springfield, NJ1
- Old Bridge, NJ1
- Overland Park, KS1
- West Chester, PA1
- Danvers, MA1
- Alpharetta, GA1
- Piscataway, NJ1
- Charlotte, NC1
- Waltham, MA1
- Princeton, NJ1
- Maple Grove, MN1
- Rancho Santa Margarita, CA1
- Redmond, WA1
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).